Type 2 Diabetes

A look at the medical spending of more than 500 patients with type 2 diabetes who initiated therapy with real-time continuous glucose monitoring details the reductions in medical costs associated with initiation of real-time CGM.

Researchers found a significant interaction between SGLT2 inhibitors based on age and eGFR.

Fluid regulation is important to the prevention of heart failure.

Data show 37.5% of patients in study were found to have moderate to severe DD, with an average score of ≥2.

eGFR improved by 10.8% and creatinine decreased by 6.8% in patients who received PIT procedures.

A study assessing use of remote patient monitoring in patients with type 2 diabetes outlines the impact continued participation in digital monitoring programs can have on glycemic control among this patient population.

Data show consistent benefit of finerenone on kidney and CV outcomes in patients with CKD and T2D, regardless of SGLT-2i use.

The COVID-19 pandemic has increased the usage of telemedicine tools in all medical fields.

A FIDELIO-DKD analysis presented at ADA 2021 suggests the renal and cardiovascular benefits of finerenone were consistent, irrespective of background GLP-1 RA use and indicate the presence of both was associated with even greater reductions in albuminuria.

Children treated with SSRIs and SGAs concurrently demonstrate higher waist circumference, BMI, and plasma total cholesterol compared to those on monotherapy.

A study assessing factors associated with achieving recommended levels of HbA1c testing provide insight into the impact of provider type and other factors on the likelihood of having at least 2 HbA1c measurements in a year.

Over half of patients attained target A1C <7%. while a third of patients attained target A1C of <8%.

While advances in glucose-lowering therapies have been practice-changing, a new analysis suggests patients could achieve greater cost-effectiveness with older agents.

Overweight/obese patients with elevated fasting blood glucose generally present with higher degrees of insulin resistance, inflammation, adverse cardiovascular disease risk profile.

New findings show patients were able to more than halve type 2 diabetes medication while improving diabetic and cardiovascular parameters in 8 weeks.

New SUPRASS-2 findings show the dual GIP/GLP-1 agonist provided superior type 2 diabetes management outcomes at 3 different doses.

Data show no evidence of increased risk of adverse events in patients aged ≥80 years, compared to patients aged 70 - 79 years.

A comparison of 3 standard dietary strategies for weight and glycemia control showed no difference in exercise metrics.

The study author joins to highlight new ADA 2021 findings showing rivaroxaban's benefit for a subpopulation of diabetic patients.

A prespecified analysis of DAPA-CKD presented at ADA 2021 suggests use of dapagliflozin reduced the incidence of type 2 diabetes by nearly 40% among patients with chronic kidney disease but without diabetes within the phase 3 trial.

The ADA study represents the first randomized head-to-head trial directly compareding an FRC with a remix insulin analog in a population of adults with suboptimally controlled type 2 diabetes on basal insulin plus OADs.

While investigators found no differences in outcomes based on diabetes status alone, results indicated those who were not managing their diabetes had more severe outcomes and longer length of hospitalization from COVID-19.

New data presented at ADA 2021 show GLP-1RA treatment is budget neutral in comparison to SoC, citing lower inpatient and outpatient cost.